McDonnell · Therapeutic advances in endocrinology and metabolism 2022 · narrative review · n=?

Characterizing skeletal muscle dysfunction in women with polycystic ovary syndrome.

Cited 12 times in the scientific literature.

Level 5 - mechanism / opinion, no new human data

Narrative review summarizing molecular and in vivo mechanisms without systematic search methodology

PubMed 35874313 · doi:10.1177/20420188221113140 · record verified 2026-08-26

What was done

This narrative review synthesizes recent molecular and in vivo human studies examining skeletal muscle perturbations in polycystic ovary syndrome (PCOS). The authors examine the role of skeletal muscle in metabolic homeostasis, its relationship with androgen excess and mitochondrial dysfunction, and potential therapeutic implications.

What was found

The abstract reports no numerical data, effect sizes, or quantitative results. It qualitatively describes a bidirectional interplay between androgen excess and insulin resistance in women with PCOS, emphasizing that skeletal muscle exhibits metabolic and mitochondrial dysfunction contributing to systemic metabolic risk.

Why it matters

Reframing PCOS as a lifelong metabolic condition involving skeletal muscle dysfunction helps clarify tissue-specific drivers of insulin resistance and identifies potential molecular targets for future intervention.

Limits

As a narrative review, this paper presents no new experimental data, sample sizes, or systematic quantitative synthesis. The abstract notes that underlying molecular mechanisms remain largely unelucidated and that major knowledge gaps persist.

Cited by